Clinical trial studies immunotherapy for head and neck cancer caused by HPV


Image credit: iStock

Patients with head and neck cancer caused by human papillomavirus-16 may be eligible to participate in a new clinical trial at the NIH Clinical Center.

Christian S. Hinrichs, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is leading a study of a T-cell therapy for oropharyngeal cancer caused by the human papillomavirus (HPV) type 16. The oropharynx is the area of the throat at the back of the mouth, including the soft palate, the base of the tongue and the tonsils. Study patients will undergo a procedure called leukapheresis. In this procedure, blood is removed from a vein through an IV catheter connected to a machine that extracts T cells (a type of immune-system cell) and returns the remaining blood to the body. The collected T cells are then modified in a lab to target HPV-associated cancer. The modified cells (E7 TCR T cells) are grown in the lab for about two weeks then given back to the patient through an IV. While the cells are being modified, patients will receive two types of chemotherapy to make the E7 TCR T cells better able to fight cancer. The aim of the study is to see if E7 TCR T cells can be given safely without delaying standard treatments (surgery or radiation with chemotherapy) for oropharyngeal cancer caused by HPV-16. identifier: NCT04015336
NCI Protocol ID: NCI-19-C-0122
Official Title: A Phase II Study of E7 TCR T Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer

The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.   

For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.

Summary Posted: Wed, 06/24/2020